Skip to main content
SpringerLink
Log in

Implantable Drug Delivery Systems for Cancer Pain and End of Life Care

  • Chapter
  • First Online:
Deer's Treatment of Pain

  • 154 Accesses

Abstract

Despite significant improvements in cancer pain management with the introduction of the World Health Organization (WHO) Step Ladder in 1984, 10–20% of cancer patients experience severe pain. For these patients, and for those who may not be able to tolerate comprehensive medical management, intrathecal therapy may be an integral component of their pain management. In this chapter, we discuss the general presentation of cancer pain, indications and uses for IDDS, surgical considerations for cancer pain patients, efficacy and evidence for IDDS in cancer pain, alternatives such as externalized neuraxial therapy, and considerations for end of life care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Recommended Reading

  1. Bentley JN, Viswanathan A, Rosenberg WS, Patil PG. Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review. Pain Med. 2014;15(9):1488–95.

    Article  Google Scholar 

  2. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105(1):169–78.

    Article  Google Scholar 

  3. Bolash R, Udeh B, Saweris Y, Guirguis M, Dalton JE, Makarova N, Mekhail N. Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management: a retrospective analysis of 365 patients. Neuromodulation. 2015;18(2):150–5.

    Article  Google Scholar 

  4. Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit. Pain Med. 2013;14(4):478–86.

    Article  Google Scholar 

  5. Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283–312.

    PubMed  Google Scholar 

  6. Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96–132.

    Article  Google Scholar 

  7. Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20(2):155–76.

    Article  Google Scholar 

  8. Engle MP, Vinh BP, Harun N, Koyyalagunta D. Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center. Pain Physician. 2013;16(3):251–7.

    PubMed  Google Scholar 

  9. Mueller-Schwefe G, Hassenbusch SJ, Reig E. Cost effectiveness of intrathecal therapy for pain. Neuromodulation. 1999;2(2):77–87.

    Article  CAS  Google Scholar 

  10. Payne WG, Naidu DK, Wheeler CK, Barkoe D, Mentis M, Salas RE, et al. Wound healing in patients with cancer. Eplasty. 2008;8:e9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206003/.

    PubMed  PubMed Central  Google Scholar 

  11. Seretny M, Currie GL, Sena ES. Incidence, prevalence, and predictors of chemotherapy- induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70.

    Article  Google Scholar 

  12. Shaiova L. Difficult pain syndromes: bone pain, visceral pain, and neuropathic pain. Cancer J. 2006;12(5):330–40.

    Article  CAS  Google Scholar 

  13. Smith TJ, Staats PS, Deer T, Sterns LJ, Boortz-Marx RL, Buchser E, Catala E, Bryce DA, Coyne PJ, Pool GE. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9.

    Article  CAS  Google Scholar 

  14. Stearns L, Boortz-Marx R, Du Pen S, Friehs G, Gordon M, Halyard M, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3(6):399–408.

    CAS  PubMed  Google Scholar 

  15. Stearns LJ, Hinnenthal JA, Hammond K, Berryman E, Janjan NA. Health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management. Neuromodulation. 2016;19(2):196–205.

    Article  Google Scholar 

  16. Zheng S, He L, Yang X, Li X, Yang Z. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine. 2017;96(11):e6354.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesia and Perioperative Care, Anesthesia and Pain Medicine, University of California at San Francisco, San Francisco, CA, USA

    Ann Cai Shah

  2. Department of Anesthesia, Pain Management Clinic, Grady Hospital, Atlanta, GA, USA

    Kenneth Ike

  3. Center for Pain and Supportive Care, Phoenix, AZ, USA

    Lisa Stearns

  4. Department of Anesthesia and Perioperative Care, University of California at San Francisco, San Francisco, CA, USA

    Lawrence R. Poree

Authors
  1. Ann Cai Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Ike
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa Stearns
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lawrence R. Poree
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence R. Poree .

Editor information

Editors and Affiliations

  1. The Spine and Nerve Center of the Virginias, Charleston, WV, USA

    Timothy R. Deer

  2. Evolve Restorative Center, Santa Rosa, CA, USA

    Jason E. Pope

  3. Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA

    Tim J. Lamer

  4. Pain Diagnostics and Interventional Care, Sewickley, PA, USA

    David Provenzano

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shah, A.C., Ike, K., Stearns, L., Poree, L.R. (2019). Implantable Drug Delivery Systems for Cancer Pain and End of Life Care. In: Deer, T., Pope, J., Lamer, T., Provenzano, D. (eds) Deer's Treatment of Pain. Springer, Cham. https://doi.org/10.1007/978-3-030-12281-2_83

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-12281-2_83

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-12280-5

  • Online ISBN: 978-3-030-12281-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation